Magic mushroom compound tested for Parkinson's depression

NCT ID NCT07610369

Recruiting now Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can improve depression in people with Parkinson's disease. Forty participants will receive a low to high dose with psychological support. The study measures changes in depression severity and tracks any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment for depression in people with Parkinson's disease.
What could go wrong: This is a small, early-phase trial with only 40 people. It may not show clear benefit, and psilocybin can cause temporary anxiety or confusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder movement disorder Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.